SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: George T. Santamaria who wrote (5251)9/3/1998 10:53:00 AM
From: Bhag Karamchandani  Read Replies (2) of 6136
 
"Agouron still has to deliver on AG3340 in a timely manner and the divisional proposal won't change a thing." I tend to agree. Here's why.

My informal monitoring of over two dozen biotechs reinforces your argument- to the extent that incremental revenues contribute only marginally to a stock's price- relative to new drug approvals. Yesterday's FDA approval of two drugs bears and its impact on price also bears this out.

IF AG3340 is going the way of Thymatiq( and I have ABSOLUTELY no information one way or another) then it may be in the best interest of its shareholders for AGPH to abort AG 3340 PIII trials now, while the stock price appears to be irrationally depressed. Of course, it would also prove embarrassing for the proposed Oncology Division to have two strike outs.But it would be a double blow to long suffering (pun intended)shareholders to suffer another setback - assuming an interim stock price recovery if and when the market recovers.
ALL THIS IS SIMPLY AN EXPRESSION OF AN OPINION. NO MORE. EMOTIONAL LONGS ARE REQUESTED TO DISREGARD THIS IF YOU DON'T AGREE.

"their basic mission, which used to be building an R&D pipeline which cranks out two products a year". It was this technological promise which attracted, and so far, has disappointed me too. One drug approval in over twelve years. In fairness to AGPH, few developmental biotechs have lived up to their promised potential and AGPH has done better than most as far as revenue generation goes.

Good luck to all.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News